Metavia INC

MetaVia Inc. announced that all patients in Part 3 of its Phase 1 obesity trial for DA-1726 have completed dose titration, with topline data expected in Q4 2026.

Metavia Inc. has filed a prospectus supplement for an at-the-market offering of up to $4 million in common stock, with legal counsel providing an opinion on the validity of the shares.

MetaVia Inc. announced that its stockholders approved an amendment to its 2022 Equity Incentive Plan, increasing the share reserve by 200,000 shares, and also approved a reverse stock split proposal.

MetaVia Inc. announced new late-breaking data for its obesity and metabolic disease portfolio, including positive Phase 1 results for DA-1726 and preclinical combination data for vanoglipel.

MetaVia Inc. announced new Phase 1 data for its dual agonist DA-1726 at EASL 2026, showing significant weight reduction and early liver improvements.

MetaVia Inc. announced that three late-breaking abstracts for its cardiometabolic assets, DA-1726 and vanoglipel, have been accepted for poster presentations at the American Diabetes Association's 2026 Scientific Sessions.

MetaVia Inc. reported a net loss of $3.8 million for Q1 2026, with operating expenses increasing slightly, while cash reserves remain a concern for ongoing operations.

MetaVia Inc. reports reduced net losses but raises substantial doubt about its ability to continue as a going concern, despite positive clinical trial updates for its cardiometabolic drug candidates.

MetaVia Inc. reported a significant reduction in net loss for Q2 2025, driven by decreased R&D expenses, and secured $9.1 million in net proceeds from a private placement, though a going concern warning persists.

MetaVia Inc. announces its Q1 2025 financial results, showcasing a decrease in net loss compared to the previous year and providing updates on its DA-1241 and DA-1726 clinical trials.

NeuroBo Pharmaceuticals' Q3 2024 report reveals a significant increase in research and development expenses as the company advances its clinical trials for MASH and obesity treatments.

NeuroBo Pharmaceuticals' Q2 2024 report reveals a significant increase in research and development expenses due to ongoing clinical trials for their MASH and obesity treatments, alongside a recent $20 million capital raise.

MetaVia Inc. reported positive clinical trial results for its MASH and obesity drug candidates, vanoglipel (DA-1241) and DA-1726, but faces substantial doubt about its ability to continue as a going concern due to recurring net losses and a need for additional capital.

MetaVia Inc. announces positive clinical trial results for its MASH and obesity programs, alongside a strategic realignment and corporate name change.

NeuroBo Pharmaceuticals, a clinical-stage biotech company, released its 2023 annual report, highlighting progress in its cardiometabolic drug development programs and ongoing financial challenges.

Director James Tursi was granted 17,186 restricted stock units under MetaVia Inc.'s 2022 Equity Incentive Plan.

Director D. Gordon Strickland was granted 17,186 restricted stock units in MetaVia Inc. as part of the company's 2022 Equity Incentive Plan.

Director Michael Salsbury was granted 17,186 restricted stock units under the MetaVia Inc. 2022 Equity Incentive Plan.

Director Jason L. Groves was granted 17,186 restricted stock units under MetaVia Inc.'s 2022 Equity Incentive Plan.

Director Andrew Koven was granted 17,186 restricted stock units under MetaVia Inc.'s 2022 Equity Incentive Plan.

Director Mark A. Glickman was granted 17,186 restricted stock units in MetaVia Inc. as part of the company's 2022 Equity Incentive Plan.

MetaVia Inc. is holding its 2026 Annual Meeting of Stockholders on June 8, 2026, to vote on director elections, auditor ratification, a reverse stock split, and equity plan amendments.

MetaVia Inc. is calling for its 2025 Annual Meeting of Stockholders to vote on critical proposals including a reverse stock split to meet Nasdaq listing requirements and the approval of shares issued in a recent private placement to fund ongoing operations.

NeuroBo Pharmaceuticals is holding a special meeting on September 18, 2024, to seek stockholder approval for the issuance of shares related to warrants issued in private placements.

NeuroBo Pharmaceuticals announces its 2024 annual meeting of stockholders to be held virtually on June 7, 2024, featuring proposals for director elections, auditor ratification, and equity incentive plan amendment.

MetaVia Inc. filed an S-1MEF to register an additional $6.9 million in Class A and Class B Units, including common stock and warrants, for a public offering.

MetaVia Inc. announced a public offering of Class A and Class B Units to raise approximately $6.0 million for working capital and clinical development of its cardiometabolic drug candidates, despite ongoing net losses and a 'going concern' warning.

MetaVia Inc. announced a public offering of up to 1.57 million units to fund its clinical programs, following positive top-line data from its Phase 1 trial for obesity and Phase 2a trial for MASH.

NeuroBo Pharmaceuticals has filed a registration statement for the resale of up to 17,175,579 shares of its common stock by selling securityholders, following a recent private placement.

Dong-A ST Co., Ltd. and Dong-A Socio Holdings Co., Ltd. have significantly increased their combined beneficial ownership in MetaVia, Inc. to 75.8% through a new securities purchase agreement, including the acquisition of pre-funded warrants.

Armistice Capital and Steven Boyd updated their passive ownership in MetaVia Inc., reporting a 4.99% stake as of June 30, 2025.

Armistice Capital, LLC and its managing member Steven Boyd have filed an amended Schedule 13G, disclosing a 9.99% beneficial ownership stake in MetaVia Inc.'s common stock as of March 31, 2025.

Armistice Capital, LLC and Steven Boyd have jointly disclosed a passive beneficial ownership of 9.99% of MetaVia Inc.'s common stock as of December 31, 2024.